The Montalcino Aortic Consortium (MAC) formed in 2013 around the need for international cooperation in the study of human diseases that affect the aorta and its major branches and that are largely determined by variation in genes.

MAC is a consortium of prominent clinical, basic and translational investigators from academic medical centers around the world committed to diagnosing and managing aortic disorders and discovering their genetic causes and modifiers.

The membership in MAC is voluntary and offered to experienced and inquisitive researchers and clinicians pledged to collaboration in improving management and outcome for people with thoracic aortic diseases.